Celyad Oncology SA
CLYYF
$0.20
-$0.21-51.22%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 201.50K | 201.10K | 201.30K | 140.80K | 77.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 201.50K | 201.10K | 201.30K | 140.80K | 77.90K |
| Cost of Revenue | 11.90K | 12.20K | 12.90K | 24.80K | 36.80K |
| Gross Profit | 189.60K | 188.90K | 188.40K | 116.10K | 41.20K |
| SG&A Expenses | 3.42M | 3.40M | 3.46M | 4.07M | 4.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -326.80K | -371.40K | -420.80K | -346.60K | -269.30K |
| Total Operating Expenses | 7.21M | 6.80M | 6.55M | 7.55M | 8.53M |
| Operating Income | -7.01M | -6.60M | -6.35M | -7.41M | -8.45M |
| Income Before Tax | -7.03M | -6.58M | -6.30M | -7.39M | -8.46M |
| Income Tax Expenses | -- | -- | -- | -33.90K | -68.20K |
| Earnings from Continuing Operations | -7.03 | -6.58 | -6.30 | -7.35 | -8.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.03M | -6.58M | -6.30M | -7.35M | -8.39M |
| EBIT | -7.01M | -6.60M | -6.35M | -7.41M | -8.45M |
| EBITDA | -6.67M | -6.24M | -5.98M | -7.03M | -8.09M |
| EPS Basic | -0.17 | -0.16 | -0.15 | -0.20 | -0.25 |
| Normalized Basic EPS | -0.11 | -0.10 | -0.09 | -0.13 | -0.16 |
| EPS Diluted | -0.17 | -0.16 | -0.15 | -0.20 | -0.25 |
| Normalized Diluted EPS | -0.11 | -0.10 | -0.09 | -0.13 | -0.16 |
| Average Basic Shares Outstanding | 165.71M | 167.77M | 167.77M | 155.19M | 142.61M |
| Average Diluted Shares Outstanding | 165.71M | 167.77M | 167.77M | 155.19M | 142.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |